Exome Asset Management’s IGM Biosciences IGMS Stock Holding History

Exome Asset Management’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-135,596	Closed	-$1.13M	–	61
2023 Q4	$1.13M	Buy	+135,596	New	+$787K	1.11%	35

Other funds holding IGMS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Exome Asset Management's IGMS Position: Q1 2024 in Review

Exome Asset Management sold out of IGM Biosciences (IGMS) in Q1 2024, closing a stake of 135,596 shares — an estimated $1.13M sold.

Exome Asset Management first reported a position in IGMS in Q4 2023 and held it in 1 quarter. The position peaked at $1.13M in Q4 2023. 87 funds tracked by Wall St. Rank hold IGMS as of Q1 2024.

Exome Asset Management reported no remaining IGM Biosciences position as of Q1 2024 after selling out during the quarter.
Exome Asset Management sold 135,596 IGM Biosciences shares in Q1 2024, an estimated $1.13M.
Exome Asset Management first reported a position in IGM Biosciences in Q4 2023 and held it in 1 quarter.
Exome Asset Management's IGM Biosciences position peaked at $1.13M in Q4 2023.
87 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2024.

Based on Exome Asset Management's 13F filing for Q1 2024, filed 15 May 2024.